Incyte executive EVP & Chief Scientific Officer sells INCY shares
Incyte Corporation reported an insider stock sale by its Executive Vice President and Chief Scientific Officer.
Rhea-AI Filing Summary
Incyte Corporation reported an insider stock sale by its Executive Vice President and Chief Scientific Officer. On 12/10/2025, the officer sold 5,553 shares of common stock at $95.58 per share. On 12/11/2025, they sold another 255 shares at $94.94 per share. After these transactions, the reporting person directly beneficially owns 60,011 common shares. A footnote also identifies 59,858 additional shares of common stock issuable under previously reported restricted stock units that have not yet vested.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 255 | $94.94 | $24K |
| Sale | Common Stock | 5,553 | $95.58 | $531K |
Footnotes (1)
- F1. Includes an aggregate of 59,858 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
FAQ
What insider transaction did Incyte (INCY) disclose in this filing?
An Executive Vice President and Chief Scientific Officer of Incyte Corporation reported open-market sales of common stock in two transactions on 12/10/2025 and 12/11/2025.
Does the Incyte (INCY) executive hold any restricted stock units?
Yes. A footnote states that there are 59,858 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
What is the reporting person’s role at Incyte (INCY)?
The reporting person is identified as an Officer, serving as EVP & Chief Scientific Officer of Incyte Corporation.
Is this Incyte (INCY) insider filing made by one or multiple reporting persons?
The document indicates that the Form is filed by one reporting person, not a group.
AI-generated analysis. How Rhea-AI works. Not financial advice.